학술논문

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Kelley, Robin KateUeno, MakotoYoo, ChanghoonFinn, Richard SFuruse, JunjiRen, ZhenggangYau, ThomasKlümpen, Heinz-JosefChan, Stephen LOzaka, MasatoVerslype, ChrisBouattour, MohamedPark, Joon OhBarajas, OlgaPelzer, UweValle, Juan WYu, LiMalhotra, UshaSiegel, Abby BEdeline, JulienVogel, ArndtAkce, MehmetAles Diaz, InmaculadaAlves, GustavoAnand, SumitraArslan, CagatayAsselah, JamilAssenat, EricAubin, FrancineBai, Li-YuanBai, YuxianBarajas, OlgaBates, SusanBegbie, StephenBen-Aharon, IritBeri, NinaBerres, Marie-LuiseBlanc, Jean-FredericBorbath, IvanBordonaro, RobertBouattour, MohamedBrandi, GiovanniBurgoyne, AdamButthongkomvong, KritiyaCamandaroba, MarcosCao, KeCarballido, MarcelaChan, Stephan LamChen, Jen-ShiChen, Ming-HuangChen, XiaomingCheng, AshleyChiu, Tai-JanChoi, Hye JinChon, Hong JaeCollignon, JoelleCubillo Gracian, AntonioDavis, Sarahde Carvalho, Ricardo Saraivade Groot, D.J.A.Demols, AnneDe Vos, JudithDiab, MariaEasaw, JacobEatock, MartinEdeline, JulienElias, RawadEskens, FredericusFalcone, AlfredoFernandez, PlinioFinn, RichardFranke, FabioFurukawa, MasayukiFuruse, JunjiGbolahan, OlumideGeboes, KarenGeneser, Keri-LeeGeng, ZhiminGeva, RavitGillmore, RoopinderGoetze, ThorstenGou, HongfengGrasselli, JulietaGu, ShanzhiGumus, MahmutHaj Mohammad, NadiaHao, ChunyiHarputluoglu, HakanHatoum, HassanHeinemann, VolkerHo, Wang KwongHsu, ChiunHubert, AyalaHwang, JuneulInanc, MevludeIseas, SoledadJeyasingam, VaishnaviJimenez Fonseca, PaulaJoubert, WarrenJuengsamarn, JitladaKaen, DiegoKanai, MasashiKasper-Virchow, StefanKazemi, GhazalehKelleher, FergalKelley, RobinKim, Jin WonKim, Jong GwangKinupe Abrahao, Ana BeatrizKlumpen, HeinzKochenderfer, MarkKose, FatihLam, Ho ChingLee, Choong-kunLee, Hyun WooLee, MargaretLee, Myung AhLee, Wai Man SarahLe Sourd, SamuelLi, DongliangLi, WeiLiang, HoujieLiang, TingboLim, Chun SenLingerfelt, BrianLopez, CharlesLow, JohnMacarulla Mercade, TeresaMalka, DavidMao, YiminMasi, GianlucaMcCune, StevenMcDermott, RayMcWhirter, ElaineMendez, GuillermoMilella, MicheleMizuno, NobumasaMizutani, TomonoriMoniz, CamilaMorales, LuisaMunoz Martin, Andres JesúsNervi, BrunoNgamphaiboon, NuttapongOh, Sang CheulOksuzoglu, BernaOutlaw, DarrylOzaka, MasatoOzguroglu, MustafaOzyilkan, OzgurPainemal, ClaudioPan, YueyinPark, Joon OhPelzer, UwePeng, ChuangPetorin, CarolinePezet, DenisPower, DerekQin, ShukuiRen, ZhenggangRoohullah, AflahRyu, HyewonSalman, PamelaSasaki, MitsuhitoSasidharan, RitaSatoh, TarohSchulze, KorneliusScott-Brown, MartinSegovia, RubenSeufferlein, ThomasSiena, SalvatoreSinapi, IsabelleSmolenschi, CristinaSong, TianqiangSookprasert, AumkhaeSoparattanapaisarn, NopadolStarling, NaureenStein, StaceyStemmer, SalomonSu, HaichuanSugimoto, RieSuksombooncharoen, ThatthanTam, VincentTan, Ai LianTan, Chih KiangTanasanvimon, SuebpongTonini, GiuseppeTortora, GiampaoloTsuji, AkihitoUeno, MakotoUribe, RodrigoVenerito, MarinoVerdaguer Mata, HelenaVerslype, ChrisVictorino, Ana PaulaVogel, ArndtWade, JamesWaldschmidt, Dirk ThomasWang, LuWan Isahk, Wan ZamaniahWasan, HarpeetWeschenfelder, RuiWong, Chun YinWong, Yoke FuiYalcin, SuayibYanez Weber, PatricioYang, XuezhongYasui, HisateruYau, ThomasYazici, OzanYen, Chia-JuiYing, JieerYoo, ChanghoonYu, WenchangZhao, Haitao
Source
The Lancet; June 2023, Vol. 401 Issue: 10391 p1853-1865, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.